HCM
TEVA icon

Highlander Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Highlander Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.02M Buy
72,100
+9,250
+15% +$117K 0.35% 64
2023
Q4 		$656K Sell
62,850
-500
-0.8% -$4.67K 0.23% 94
2023
Q3 		$646K Buy
63,350
+9,000
+17% +$83.8K 0.25% 87
2023
Q2 		$409K Sell
54,350
-300
-0.5% -$2.43K 0.19% 103
2023
Q1 		$484K Hold
54,650
– – 0.24% 95
2022
Q4 		$498K Sell
54,650
-2,100
-4% -$18.3K 0.26% 81
2022
Q3 		$458K Buy
56,750
+2,800
+5% +$24.8K 0.26% 82
2022
Q2 		$406K Sell
53,950
-540
-1% -$4.71K 0.22% 94
2022
Q1 		$512K Sell
54,490
-1,000
-2% -$8.35K 0.24% 87
2021
Q4 		$444K Sell
55,490
-200
-0.4% -$1.8K 0.21% 95
2021
Q3 		$542K Sell
55,690
-900
-2% -$8.43K 0.27% 80
2021
Q2 		$560K Hold
56,590
– – 0.28% 80
2021
Q1 		$653K Buy
56,590
+33,800
+148% +$388K 0.34% 70
2020
Q4 		$220K Sell
22,790
-1,250
-5% -$12K 0.12% 128
2020
Q3 		$217K Sell
24,040
-1,500
-6% -$15.9K 0.13% 128
2020
Q2 		$315K Hold
25,540
– – 0.2% 107
2020
Q1 		$229K Sell
25,540
-1,250
-5% -$12.8K 0.16% 119
2019
Q4 		$263K Sell
26,790
-8,200
-23% -$73.2K 0.15% 120
2019
Q3 		$241K Sell
34,990
-4,500
-11% -$34.5K 0.15% 132
2019
Q2 		$364K Buy
39,490
+3,050
+8% +$36.8K 0.22% 108
2019
Q1 		$571K Sell
36,440
-3,250
-8% -$57.3K 0.35% 75
2018
Q4 		$618K Sell
39,690
-1,800
-4% -$36.9K 0.41% 65
2018
Q3 		$894K Sell
41,490
-23,400
-36% -$543K 0.5% 51
2018
Q2 		$1.58M Buy
64,890
+1,000
+2% +$20.4K 0.89% 22
2018
Q1 		$1.08M Sell
63,890
-4,100
-6% -$80.1K 0.64% 37
2017
Q4 		$1.29M Sell
67,990
-11,454
-14% -$172K 0.94% 16
2017
Q3 		$1.4M Buy
79,444
+3,100
+4% +$69.8K 1.09% 11
2017
Q2 		$2.54M Buy
76,344
+7,450
+11% +$231K 2% 4
2017
Q1 		$2.21M Buy
68,894
+18,240
+36% +$622K 1.81% 4
2016
Q4 		$1.84M Buy
50,654
+31,500
+164% +$1.26M 1.59% 5
2016
Q3 		$881K Buy
19,154
+8,950
+88% +$467K 0.79% 25
2016
Q2 		$513K Buy
10,204
+1,650
+19% +$87.8K 0.47% 55
2016
Q1 		$458K Buy
8,554
+8,400
+5,455% +$493K 0.43% 62
2015
Q4 		$10K Hold
154
– – 0.01% 647
2015
Q3 		$8K Hold
154
– – 0.01% 690
2015
Q2 		$9K Hold
154
– – 0.01% 681
2015
Q1 		$10K Sell
154
-100
-39% -$5.81K 0.01% 657
2014
Q4 		$15K Hold
254
– – 0.01% 609
2014
Q3 		$13.7K Hold
254
– – 0.01% 604
2014
Q2 		$13.3K Hold
254
– – 0.01% 596
2014
Q1 		$13.5K Hold
254
– – 0.01% 596
2013
Q4 		$10.2K Hold
254
– – 0.01% 648
2013
Q3 		$9.62K Sell
254
-100
-28% -$3.9K 0.01% 677
2013
Q2 		$13.9K Buy
+354
New +$13.8K 0.01% 577

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Highlander Capital Management's TEVA Position: Q1 2024 in Review

Highlander Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 15% in Q1 2024, buying an estimated $117K and bringing the position to 72,100 shares worth $1.02M. The position accounts for 0.35% of the portfolio, ranked #64.

Highlander Capital Management first reported a position in TEVA in Q2 2013 and has held it in 44 quarters since. The position peaked at $2.54M in Q2 2017. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Highlander Capital Management held 72,100 shares of Teva Pharmaceuticals worth $1.02M as of Q1 2024.
  • Highlander Capital Management bought 9,250 Teva Pharmaceuticals shares in Q1 2024, an estimated $117K.
  • Teva Pharmaceuticals made up 0.35% of Highlander Capital Management's portfolio in Q1 2024, its #64 holding.
  • Highlander Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Highlander Capital Management's Teva Pharmaceuticals position peaked at $2.54M in Q2 2017.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.